Deconvolution of polyclonal hepatitis C virus-specific neutralizing antibodies in plasma

Case ID:
C15909

Unmet Need: Hepatitis C Virus (HCV) is a leading cause of liver cancer worldwide. Although treatments have been developed, these drugs do not protect against reinfection and are often cost prohibitive to patients. Therefore, there is an urgent need for the development of an effective HCV vaccine. There is currently no efficient method to assess antibody responses to candidate vaccines.

 

Technical Details: Researchers at Johns Hopkins University have developed a novel method to identify protective antibody responses associated with HCV clearance. Application of the high-throughput method allows for deconvolution of polyclonal anti-HCV neutralizing antibodies (NAbs) in plasma and has identified broadly neutralizing antibody (bNAb) signatures that contribute to clearance of the virus. As shown in plasma from patients who naturally cleared infection, multiple bNAb combinations are associated with greater plasma neutralizing breadth and with HCV clearance. The method further delineates epitopes on the HCV envelope proteins that induce the identified bNAb signatures associated with clearance. In addition, the high-throughput method can be used to assess HCV vaccine efficacy through determination of bNAb signatures elicited by vaccine candidates.

 

Value Proposition:

  • High-throughput method to assess bNAb signatures associated with HCV clearance
  • Method can also identify effective HCV bNAb responses after vaccination trials

Looking for Partners to: Develop & commercialize the technology as a novel method to assess antibody responses to candidate HCV vaccines.

Stage of Development: Pre-Clinical

Data Availability: Method validated using HCV infected human plasma

Inventors: Justin Bailey, Valerie Kinchen, Guido Massaccesi, Stuart Ray, Andrea Cox

Patent Status: US Pending

Publication(s): Kinchen VJ, Massaccesi G, Flyak AI, Mankowski MC, Colbert MD, Osburn WO, Ray SC, Cox AL, Crowe JE, Bailey JR. (2019) Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance. J CLin Invest 129(11):4786-4796.

 

Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
METHODS AND COMPOSITIONS FOR HEPATITIS C VIRUS (HCV) PCT: Patent Cooperation Treaty United States 17/630,104   1/25/2022     Pending
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Vera Sampels
vsampel2@jhu.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum